Clinical Evidence

In September 2019, a 2-year-old boy with epidermolysis bullosa (EB) presented with a partial-thickness armpit blister.

After 2 days of standard-of-care treatment, his armpit turned into a full-thickness blister, resulting in a macerated wound.

Microlyte^® was suggested as an alternate therapy, and permission was granted 5 days later, during which time one more standard-of-care dressing change occurred.

Microlyte^® was applied at days 1, 3, 4, 10 and 12 in combination with Kurlex gauaze bandages

Treatment with Microlyte^® appeared to contribute to significant closure of the EB blister wound.

EB is a rare genetic disease of connective tissue that involves severe blistering of the skin from minor damage such as heat, rubbing, scratching or adhesive tape removal.

In addition to enduring daily painful dressing changes, EB patients are at constant risk for infection and sepsis due to multiple open wounds.

Because there is no cure, treatment focuses on caring for blisters, preventing new ones and protecting non-blistered skin.

Microlyte^® application to a severe full-thickness blister, lead to unprecedented improvement in patient’s wounds.

Importantly, because Microlyte^® is completely bioresorbable, the matrix did not need to be removed, resulting in decreased pain and increased quality of life.

Microlyte^® shows promise as an adjunct therapy for patients with partial- and full-thickness wounds arising from epidermolysis bullosa.